Isabelle Fleury
Overview
Explore the profile of Isabelle Fleury including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
2191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Castonguay M, Bernard L, Corriveau M, Castonguay A, Quenneville G, Cohen S, et al.
Transfusion
. 2025 Jan;
PMID: 39876551
Background: Cold agglutinin disease (CAD) or syndrome (CAS) can be particularly challenging when autologous stem cell transplant (ASCT) is needed. Standard peripheral blood stem cell (PBSC) collection and manipulation involve...
2.
Bartlett N, Hahn U, Kim W, Fleury I, Laribi K, Bergua J, et al.
J Clin Oncol
. 2025 Jan;
43(9):1061-1072.
PMID: 39772655
Purpose: In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy...
3.
Ghosh N, Eyre T, Brown J, Lamanna N, Manzoor B, Coombs C, et al.
Am J Hematol
. 2024 Dec;
100(3):511-515.
PMID: 39698781
No abstract available.
4.
Kuruvilla J, Rushton C, Villa D, Aslam M, Prica A, Abdel Samad N, et al.
Br J Haematol
. 2024 Sep;
205(5):2067-2071.
PMID: 39267295
In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial...
5.
Morschhauser F, Dahiya S, Palomba M, Garcia-Sancho A, Reguera Ortega J, Kuruvilla J, et al.
Nat Med
. 2024 Jul;
30(8):2374.
PMID: 38982297
No abstract available.
6.
Morschhauser F, Dahiya S, Palomba M, Garcia-Sancho A, Reguera Ortega J, Kuruvilla J, et al.
Nat Med
. 2024 Jun;
30(8):2199-2207.
PMID: 38830991
An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from first-line immunochemotherapy or disease...
7.
Stewart D, Kuruvilla J, Lee D, Dudebout J, Chua N, Larouche J, et al.
Br J Haematol
. 2024 May;
205(3):881-890.
PMID: 38802107
The Canadian Cancer Trials Group (CCTG) LY.17 is an ongoing multi-arm randomized phase II trial evaluating novel salvage therapies compared with R-GDP (rituximab, gemcitabine, dexamethasone and cisplatin) in autologous stem...
8.
Nowakowski G, Yoon D, Mondello P, Joffe E, Peters A, Fleury I, et al.
Ann Hematol
. 2023 Jul;
102(9):2643-2644.
PMID: 37432417
No abstract available.
9.
Lachaine J, Guinan K, Aw A, Banerji V, Fleury I, Owen C
Curr Oncol
. 2023 May;
30(5):4483-4498.
PMID: 37232797
Background: Continuous oral targeted therapies (OTT) represent a major economic burden on the Canadian healthcare system, due to their high cost and administration until disease progression/toxicity. The recent introduction of...
10.
Nowakowski G, Yoon D, Mondello P, Joffe E, Peters A, Fleury I, et al.
Ann Hematol
. 2023 May;
102(7):1773-1787.
PMID: 37171597
RE-MIND2 (NCT04697160) compared patient outcomes from the L-MIND (NCT02399085) trial of tafasitamab+lenalidomide with those of patients treated with other therapies for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are...